The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, the illness caused by the virus. Months after recovery from mild Covid-19, when antibody levels in the blood have declined, immune cells in bone marrow remain ready to pump out new antibodies against the coronavirus,.
Xinhua world news summary at 0030 GMT, May 25
Xinhua
25 May 2021, 10:30 GMT+10
MOSCOW Russian Security Council Secretary Nikolai Patrushev met with U.S. National Security Advisor Jake Sullivan on Monday in Geneva where the two discussed strategic stability issues, the Russian Security Council said. The meeting that took place became an important step leading to the preparation of the planned Russia-U.S. summit, the date and venue of which will be announced later, the council said in a statement. (Russia-U.S.-Strategic stability) - - - - WASHINGTON At least 25 states reported that more than half of their adult population had been fully vaccinated as of Sunday, according to the latest data published by the U.S. Centers for Disease Control and Prevention (CDC).
People who had mild cases of COVID-19 have develop antibody-producing cells that can last a lifetime, according to a new study from the Washington University School of Medicine
Published May 25, 2021, 9:11 AM
CHICAGO, United States (Xinhua) Months after recovering from mild cases of COVID-19, people still have immune cells in their body pumping out antibodies against the virus that causes COVID-19, and such cells could persist for a lifetime, according to a study from Washington University School of Medicine in St. Louis.
To find out whether those who have recovered from mild cases of COVID-19 harbor long-lived plasma cells that produce antibodies specifically targeted to SARS-CoV-2, the virus that causes COVID-19, the researchers started on a project to track antibody levels in blood samples from COVID-19 survivors.
The research team already had enrolled 77 participants who were giving blood samples at three-month intervals starting about a month after initial infection. Most participants had had mild cases of COVID-19, and only six had been hospitalized.